Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended			209 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2011
Cash flows from operating activities:
Net loss	$ (3,803)	$ (6,597)	$ (15,626)	$ (262,232)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	2	21	208	2,245
Disposal of assets	(14)	83	69	286
Compensation expense related to equity awards	114	626	1,323	11,398
Amortization of deemed discount on convertible debentures	0	0	0	6,470
Amortization of deferred issuance cost	0	0	0	1,157
Common stock issued for 401k/401m plan	0	43	98	1,550
Common stock and options issued as consideration for license fees and amendments, milestone payment, interest, note repayment and services	0	0	0	2,926
Expense related to warrants issued as consideration to consultants	0	0	0	4,369
Expense related to warrants issued to a director for successful closure of merger	0	0	0	570
Expense related to stock options issued	0	0	0	5,718
Expense related to common stock issued for the purchase of technology	0	0	0	1,848
Common stock issued as consideration for In-Process R&D	0	0	0	2,809
Deferred compensation expense related to options issued	0	0	0	1,210
Changes in assets and liabilities:
Prepaid expenses	40	109	53	(60)
Deposits	18	20	20	(10)
Other receivable	1	80	(81)	0
Accounts payable	(194)	67	(187)	714
Accrued expenses	(659)	(145)	(479)	300
Other Liabilities	(7)	29	0	22
Net cash used in operating activities	(4,502)	(5,664)	(14,602)	(218,710)
Cash flows provided by investing activities:
Proceeds from sale of property and equipment	49	26	197	272
Purchase of property and equipment	0	0	(9)	(2,825)
Net cash provided by (used in) investing activities	49	26	188	(2,553)
Cash flows from financing activities:
Contributions from stockholder	0	0	0	104
Restricted Cash	(2,825)	34	0	(2,825)
Redeemable Preferred Stock	2,478	0	0	2,478
Restricted Cash used in settlement of warrant liability	338	0	0	338
Restricted Cash used in settlement of stock related to reverse stock split	6	0	0	6
Restricted Cash used for bank fees	3	0	0	3
Net proceeds from sale of preferred stock	0	0	0	4,000
Net proceeds from sale of common stock	0	1,789	0	185,323
Net proceeds from issuance of convertible debentures and warrants	0	0	0	9,214
Purchase of treasury stock	0	0	0	(346)
Proceeds from issuance of debt	0	0	0	371
Net proceeds from recapitalization	0	0	0	6,271
Net proceeds from warrants/options exercised	0	0	0	17,796
Net cash provided by financing activities	0	1,823	0	222,733
Net increase (decrease) in cash and equivalents	(4,453)	(3,815)	(14,414)	1,470
Cash and equivalents at beginning of period	5,923	9,738	24,152	0
Cash and equivalents at end of period	1,470	5,923	9,738	1,470
Supplemental disclosure of cash flow information:
Interest paid	0	0	0	388
Conversion of debt to equity	0	0	0	10,371
Warrants issued to consultants in lieu of cash, no vesting	0	0	0	559
Warrants issued in lieu of cash, commissions on private placement	0	0	0	733
Warrants issued in connection with convertible debentures	$ 0	$ 0	$ 0	$ 371